title: Pharmacotherapy and herbal treatment of benign prostatic hyperplasia.
abstract: Benign prostatic hyperplasia (BPH) is the most common tumor in aging men, and is associated with lower urinary tract symptoms (LUTS). Treatment options include watchful waiting, life-style modification, pharmacologic treatment, and surgery. Alpha-adrenergic receptor blockers (α-blockers) decrease LUTS and increase urinary flow rates in men with symptomatic BPH. 5-Alpha-reductase inhibitors (5-ARIs) decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume. For patients with moderate to severe symptoms and a large prostate, combination therapy with α-blockers and 5-ARIs can further improve clinical efficacy of treatment. Numerous plant-based products (phytomedicines) are increasingly used as an alternative or complement the conventional medication. For some patients, phosphodiesterase-5 inhibitors (PDE5-Is) or antimuscarinic agents may be added. Here, we discuss the current pharmacotherapy of BPH.
authors.affiliation: Shanghai Seventh People's Hospital, 358 Datong Road, Pudong New Area, Shanghai 200137, China.
authors.forename: Jianming
authors.initials: J
authors.lastname: Sun
authors.affiliation: Shanghai Seventh People's Hospital, Shanghai, China.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Zhang
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000529:Complementary Therapies; D004359:Drug Therapy, Combination; D029001:Herbal Medicine; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000628:therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D058986:Phosphodiesterase 5 Inhibitors